Draft Guidance on Enasidenib Mesylate

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Enasidenib mesylate

Dosage Form; Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: EQ 100 mg Base
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments:
   a.) Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with IDHIFA and for at least 1 month after the last dose of enasidenib mesylate tablet.
   b.) Ensure adequate washout periods between treatments in the crossover studies due to its long terminal elimination half-life. Also, consider using a parallel study design due to its long half-life. For long half-life drug products with low intra-subject variability in distribution and clearance, an AUC truncated to 72 hours may be used in place of AUC_{0-t} or AUC_{0-\infty}. For either a crossover or parallel study, sample collection time should be adequate to ensure completion of gastrointestinal transit of the drug product and absorption of the drug substance. Collect sufficient blood samples in the bioequivalence studies to adequately characterize the peak concentration (C_{max}) and time to reach peak concentration (t_{max}).

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: EQ 100 mg Base
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: See comments above.

Analytes to measure (in appropriate biological fluid): Enasidenib in plasma

Bioequivalence based on (90% CI): Enasidenib

Recommended Sept 2018
Waiver request of in vivo testing: EQ 50 mg base based on (i) acceptable bioequivalence studies on the EQ 100 mg base strength, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).